Russ Lebovitz

CEO & CoFounder
Russ Lebovitz

About Russ Lebovitz

Dr. Russ Lebovitz brings in-depth expertise in managing biotech companies in the diagnostics field. His broad experience spans from R&D to early-stage to commercial product launch. 

Dr. Lebovitz has spearheaded global projects for Fortune 100 companies and venture-backed startups. The visionary CEO has forged strategic relationships with pharmaceutical companies and renowned clinicians worldwide.

Before his management career, Russ worked as a senior scientist and research physician for over 15 years.

Over his illustrative career, Dr. Lebovitz served on the faculty of Baylor College of Medicine at the Texas Medical Center in Houston and The Fox Chase Cancer Center in Philadelphia.

A champion for brain health drug development, Russ also works closely with the Alzheimer’s Drug Discovery Foundation (ADDF), playing the role of the principal investigator.

Always eager to collaborate on science, Dr. Russ Lebovitz plays an active part in research projects with the Center for Neurologic Study (CNS), the Michael J. Fox Foundation (MJFF), ALS Association (Golden West Chapter), and several other  Lewy Body Dementia organizations.  

To date, Dr. Russ has appeared on 20+ brain health podcasts, spreading the message of early detection. 

Dr. Lebovitz received his M.D. and Ph.D. degrees from the Washington University School of Medicine.

"Improving the world.... One molecule at a time." - Russ Lebovitz


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.